Comparison of total drug pharmacokinetic variables for first cycles of nab-paclitaxel and sb-paclitaxel (n = 14)
| . | nab-paclitaxel . | . | . | sb-paclitaxel . | . | . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | (260 mg/m2) . | . | . | (175 mg/m2) . | . | . | . | ||||
| . | Mean . | Range . | %CV . | Mean . | Range . | %CV . | . | ||||
| T1/2 (h) | 20.0 | 15.5-31.2 | 21.3% | 20.9 | 15.7-34.0 | 21.4% | 0.53 | ||||
| Cmax (ng/mL) | 19,556.4 | 10,613.1-34,201.4 | 36.2% | 5,128.0 | 3,136.0-8,832.3 | 32.7% | <0.00001 | ||||
| Cmax/dose (ng/mL per mg/m2) | 75.2 | 40.8-131.5 | 36.2% | 29.3 | 17.9-50.5 | 32.7% | <0.00001 | ||||
| AUCINF (h*ng/mL) | 20,324.5 | 15,539.2-29,447.9 | 19.5% | 20,821.1 | 12,973.4-30,622.2 | 25.9% | 0.72 | ||||
| AUCINF_Dose (h*ng/mL per mg/m2) | 78.2 | 59.8-175.0 | 19.5% | 119.0 | 74.1-175.0 | 25.9% | 0.0001 | ||||
| Vz_obs (L/m2) | 375.4 | 269.6-571.1 | 21.9% | 270.8 | 151.0-457.2 | 61.4% | 0.003 | ||||
| Cl_obs (L/h/m2) | 13.2 | 8.8-16.7 | 17.9% | 8.9 | 5.7-13.5 | 25.7% | 0.00002 | ||||
| . | nab-paclitaxel . | . | . | sb-paclitaxel . | . | . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | (260 mg/m2) . | . | . | (175 mg/m2) . | . | . | . | ||||
| . | Mean . | Range . | %CV . | Mean . | Range . | %CV . | . | ||||
| T1/2 (h) | 20.0 | 15.5-31.2 | 21.3% | 20.9 | 15.7-34.0 | 21.4% | 0.53 | ||||
| Cmax (ng/mL) | 19,556.4 | 10,613.1-34,201.4 | 36.2% | 5,128.0 | 3,136.0-8,832.3 | 32.7% | <0.00001 | ||||
| Cmax/dose (ng/mL per mg/m2) | 75.2 | 40.8-131.5 | 36.2% | 29.3 | 17.9-50.5 | 32.7% | <0.00001 | ||||
| AUCINF (h*ng/mL) | 20,324.5 | 15,539.2-29,447.9 | 19.5% | 20,821.1 | 12,973.4-30,622.2 | 25.9% | 0.72 | ||||
| AUCINF_Dose (h*ng/mL per mg/m2) | 78.2 | 59.8-175.0 | 19.5% | 119.0 | 74.1-175.0 | 25.9% | 0.0001 | ||||
| Vz_obs (L/m2) | 375.4 | 269.6-571.1 | 21.9% | 270.8 | 151.0-457.2 | 61.4% | 0.003 | ||||
| Cl_obs (L/h/m2) | 13.2 | 8.8-16.7 | 17.9% | 8.9 | 5.7-13.5 | 25.7% | 0.00002 | ||||
Abbreviation: %CV, % coefficient of variation.